Sarcopenia Is Associated With Development of Acute-on-Chronic Liver Failure in Decompensated Liver Cirrhosis Receiving Transjugular Intrahepatic Portosystemic Shunt

INTRODUCTION: Muscle mass has been shown to be a prognostic marker in patients with liver cirrhosis. Transversal psoas muscle thickness normalized by height (TPMT/height) obtained by routine computed tomography is a simple surrogate parameter for sarcopenia. TPMT/height, however, is not sex specific, which might play a role in risk stratification. Its association with acute-on-chronic liver failure (ACLF) has not been established yet. ACLF is associated with systemic inflammatory dysregulation. This study aimed at evaluating the role of sarcopenia in ACLF development of patients with decompensated cirrhosis receiving transjugular intrahepatic portosystemic shunt (TIPS) using sex-specific TPMT/height. METHODS: One hundred eighty-six patients from the prospective Non-invasive Evaluation Program for TIPS and Follow Up Network cohort (observational, real-world TIPS cohort with structured follow-up) were analyzed. TPMT/height was measured from routine computed tomography. The sex-specific cutoff was determined to classify patients as sarcopenic and nonsarcopenic for 1-year mortality after TIPS. Clinical outcome was compared. Primary end points were ACLF and 1-year mortality after TIPS. Secondary end points were development of decompensations (hepatic encephalopathy and ascites) after TIPS. RESULTS: The sex-specific cutoff increases the diagnostic accuracy with regard to primary and secondary end points compared with the unisex cutoff. Sex-specific sarcopenia classification is an independent predictor of 1-year mortality and ACLF development in patients with cirrhosis receiving TIPS. Patients in the sarcopenia group showed significantly higher rates of mortality, ascites, overt hepatic encephalopathy, and ACLF after TIPS compared with the nonsarcopenia group. The Chronic Liver Failure Consortium Acute Decompensation score as a marker of systemic inflammation was significantly higher in sarcopenic patients. CONCLUSIONS: This study demonstrates for the first time that sarcopenia is related to ACLF development and systemic inflammation. The prognostic value of TPMT/height can be improved by using sex-specific cutoffs. ClinicalTrials.gov identifier: NCT03584204.

[1]  A. Montano‐Loza,et al.  Poor performance of psoas muscle index for identification of patients with higher waitlist mortality risk in cirrhosis , 2018, Journal of cachexia, sarcopenia and muscle.

[2]  K. Hayashi,et al.  Impact of myosteatosis on skeletal muscle volume loss in patients with chronic liver disease , 2018, Journal of gastroenterology and hepatology.

[3]  R. Moreau,et al.  Systemic Inflammation and Acute-on-Chronic Liver Failure: Too Much, Not Enough , 2018, Canadian journal of gastroenterology & hepatology.

[4]  J. Trebicka,et al.  EASL Clinical Practice Guidelines for the management of patients with decompensated cirrhosis. , 2018, Journal of hepatology.

[5]  L. Ferrucci,et al.  Inflammageing: chronic inflammation in ageing, cardiovascular disease, and frailty , 2018, Nature Reviews Cardiology.

[6]  K. Boudjema,et al.  The psoas muscle transversal diameter predicts mortality in patients with cirrhosis on a waiting list for liver transplantation: A retrospective cohort study. , 2018, Nutrition.

[7]  P. Abete,et al.  Sarcopenia: assessment of disease burden and strategies to improve outcomes , 2018, Clinical interventions in aging.

[8]  G. Herrero-Beaumont,et al.  Mediators and Patterns of Muscle Loss in Chronic Systemic Inflammation , 2018, Front. Physiol..

[9]  L. Peng,et al.  Healthy community‐living older men differ from women in associations between myostatin levels and skeletal muscle mass , 2018, Journal of cachexia, sarcopenia and muscle.

[10]  C. Strassburg,et al.  Fat‐free muscle mass in magnetic resonance imaging predicts acute‐on‐chronic liver failure and survival in decompensated cirrhosis , 2018, Hepatology.

[11]  R. Takata,et al.  Implication of exercise interventions on sleep disturbance in patients with pancreatic cancer: a study protocol for a randomised controlled trial , 2018, BMJ open gastroenterology.

[12]  M. Karsdal,et al.  Acute decompensation boosts hepatic collagen type III deposition and deteriorates experimental and human cirrhosis , 2018, Hepatology communications.

[13]  A. Montano‐Loza,et al.  Association between Low Testosterone Levels and Sarcopenia in Cirrhosis: A Cross-sectional Study. , 2018, Annals of hepatology.

[14]  L. Rossmeislová,et al.  The Role of Inflammation in Age-Related Sarcopenia , 2017, Front. Physiol..

[15]  Y. Hiasa,et al.  Efficacy of branched-chain amino acid supplementation and walking exercise for preventing sarcopenia in patients with liver cirrhosis , 2017, European journal of gastroenterology & hepatology.

[16]  Jennifer C Lai,et al.  Development of a novel frailty index to predict mortality in patients with end‐stage liver disease , 2017, Hepatology.

[17]  A. Farcomeni,et al.  Sarcopenia Is Risk Factor for Development of Hepatic Encephalopathy After Transjugular Intrahepatic Portosystemic Shunt Placement , 2017, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[18]  A. Montano‐Loza,et al.  A multicenter study to define sarcopenia in patients with end‐stage liver disease , 2017, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[19]  J. Trebicka.  Emergency TIPS in a Child-Pugh B patient: When does the window of opportunity open and close? , 2017, Journal of hepatology.

[20]  D. Samuel,et al.  A new definition of sarcopenia in patients with cirrhosis undergoing liver transplantation , 2016, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[21]  D. Thabut,et al.  Transjugular Intrahepatic Portosystemic Shunts With Covered Stents Increase Transplant-Free Survival of Patients With Cirrhosis and Recurrent Ascites. , 2017, Gastroenterology.

[22]  P. Angeli,et al.  Incidence, predictors and outcomes of acute-on-chronic liver failure in outpatients with cirrhosis. , 2017, Journal of hepatology.

[23]  P. Kamath,et al.  Time trends in the health care burden and mortality of acute on chronic liver failure in the United States , 2016, Hepatology.

[24]  P. Kamath,et al.  Acute-on-chronic liver failure in cirrhosis , 2016, Nature Reviews Disease Primers.

[25]  M. Bellis,et al.  Implementation of the Lancet Standing Commission on Liver Disease in the UK , 2015, The Lancet.

[26]  A. de Gottardi,et al.  Clinical Course of acute‐on‐chronic liver failure syndrome and effects on prognosis , 2015, Hepatology.

[27]  A. Farcomeni,et al.  Sarcopenia in liver cirrhosis: the role of computed tomography scan for the assessment of muscle mass compared with dual-energy X-ray absorptiometry and anthropometry , 2015, European journal of gastroenterology & hepatology.

[28]  Philip Wong,et al.  Hepatic encephalopathy in chronic liver disease: 2014 Practice Guideline by the American Association for the Study Of Liver Diseases and the European Association for the Study of the Liver , 2014, Hepatology.

[29]  A. Montano‐Loza,et al.  Clinical relevance of sarcopenia in patients with cirrhosis. , 2014, World journal of gastroenterology.

[30]  V. Vilgrain,et al.  Prognostic value of muscle atrophy in cirrhosis using psoas muscle thickness on computed tomography. , 2014, Journal of hepatology.

[31]  R. Moreau,et al.  Acute-on-chronic liver failure is a distinct syndrome that develops in patients with acute decompensation of cirrhosis. , 2013, Gastroenterology.

[32]  M. Dew,et al.  Objective Radiologic Assessment of Body Composition in Patients with End-Stage Liver Disease: Going Beyond the BMI , 2013, Transplantation.

[33]  V. Baracos,et al.  Severe muscle depletion in patients on the liver transplant wait list: Its prevalence and independent prognostic value , 2012, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[34]  M. Sawyer,et al.  Muscle wasting is associated with mortality in patients with cirrhosis. , 2012, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[35]  Douglas E Schaubel,et al.  Sarcopenia and mortality after liver transplantation. , 2010, Journal of the American College of Surgeons.

[36]  J. Baeyens,et al.  Sarcopenia: European consensus on definition and diagnosis , 2010, Age and ageing.

[37]  J. Baeyens,et al.  European working group on sarcopenia in older people. Sarcopenia: European consensus on definition and diagnosis: report of the European working group on sarcopenia in older people , 2010 .

[38]  Tony Reiman,et al.  Prevalence and clinical implications of sarcopenic obesity in patients with solid tumours of the respiratory and gastrointestinal tracts: a population-based study. , 2008, The Lancet. Oncology.

[39]  F. Wong,et al.  Transjugular intrahepatic portosystemic shunt for refractory ascites: a meta-analysis of individual patient data. , 2007, Gastroenterology.